News | 16 December 2024
Aster DM Healthcare launches precision oncology, offering data-driven, personalized cancer care
Harnessing advanced data analysis for early detection, prevention and better outcomes
Harnessing advanced data analysis for early detection, prevention and better outcomes
The trademark rights for these brands will be transferred to Lupin by March next year.
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
Venus Remedies secures marketing authorization in Philippines
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
Reaffirms Lupin’s commitment to sustainable resource management
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA
The celebrations began with the unveiling of the Biocon Anthem
Subscribe To Our Newsletter & Stay Updated
